A JAMA study reported concerns about how the FDA is using oncology regulatory pathways, arguing that accelerated-approval protections are being underutilized for confirmatory benefit and safety verification. The authors performed a cross-sectional analysis of 385 adult cancer drug approvals from 2006 through 2025, evaluating regulatory pathways, trial designs, and evidence quality. The research found that a decline in approvals backed by overall survival and progression-free survival has coincided with greater reliance on response rate and single-arm studies, alongside an increase in regular approvals based on weaker evidence. The authors argued that when up-front regular approval substitutes for accelerated approval mechanisms, the safety net of confirmatory trials is reduced. The paper also notes that around a quarter of the drugs were approved under accelerated pathways, with the remainder more often linked to advanced cancer indication expansions and surrogate endpoints. Chemotherapy approvals showed a diminished share over time. The study’s interpretation is aimed at policy and evidence standards for oncology drug review rather than a specific product, but it directly affects how development programs structure endpoints and post-approval obligations.